Surface Oncology, Inc.
SURFNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for SURF. That does not mean none is planned.
Get an email about SURF's next catalysts
Track Surface Oncology (SURF) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
Market Overview
Stock performance and key metrics
SURF-100 (Combination of Mycophenolic Acid and Betamethasone Sodium Phosphate)
Dry Eye Disease
SURF-201
Post-surgical Ocular Inflammation
Betamethasone Sodium Phosphate
Dry Eye Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SURF-100 (Combination of Mycophenolic Acid and Betamethasone Sodium Phosphate) | Phase 2 | Dry Eye Disease | - | - |
SURF-201 | Phase 2 | Post-surgical Ocular Inflammation | - | - |
Betamethasone Sodium Phosphate | Phase 2 | Dry Eye Disease | - | - |
Frequently asked questions
What is in Surface Oncology, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Surface Oncology, Inc.'s (SURF) pipeline across Phase 2. Its lead program is Betamethasone Sodium Phosphate (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Surface Oncology, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Surface Oncology, Inc. (SURF) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track SURF biotech catalysts?→
Add SURF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Surface Oncology, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.